Get started
Author

Joy Zhu

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
2012 · Anas Younes, Jorge Romaguera, et al. · Journal of Clinical Oncology · 142
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015 · Rami S. Komrokji, John F. Seymour, et al. · Blood · 120
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
2017 · Jeffrey R Infante, Ronald L Korn, et al. · British Journal of Cancer · 83
PDF
Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
2010 · Srdan Verstovsek, H. Joachim Deeg, et al. · Blood · 35
A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer.
2013 · Sunil R. Hingorani, William Proctor Harris, et al. · Journal of Clinical Oncology · 26
Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
2011 · Veronica Novotny-Diermayr, Nina Sausgruber, et al. · Molecular Cancer Therapeutics · 24
PDF
Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.
2010 · Anas Younes, Michelle A. Fanale, et al. · Blood · 12
Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies
2010 · Guillermo Garcia-Manero, Charles Chuah, et al. · Blood · 10
Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
2018 · Jeffrey R Infante, Ronald L Korn, et al. · British Journal of Cancer · 9
PDF
Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.
2012 · Mitesh J. Borad, Ramesh K. Ramanathan, et al. · Journal of Clinical Oncology · 9
Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).
2006 · Lubomir Sokol, Larry Cripe, et al. · Blood · 3
Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors.
2013 · Ping Jiang, Daniel C. Maneval, et al. · Cancer Research · 2
Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer.
2013 · William Proctor Harris, Sunil R. Hingorani, et al. · Journal of Clinical Oncology · 1
Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors
2012 · Daniel C. Maneval, Ramesh K. Ramanathan, et al. · Cancer Research · 1
Data from Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
2023 · Veronica Novotny-Diermayr, Nina Sausgruber, et al.
Supplementary Methods, Figures 1-2, Tables 1-2 from Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
2023 · Veronica Novotny-Diermayr, Nina Sausgruber, et al.
PDF
Supplementary Methods, Figures 1-2, Tables 1-2 from Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
2023 · Veronica Novotny-Diermayr, Nina Sausgruber, et al.
Data from Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
2023 · Veronica Novotny-Diermayr, Nina Sausgruber, et al.
Abstract 4955: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) increases tumor perfusion in mouse xenografts and phase 1 cancer patients.
2013 · Curtis B. Thompson, Patrick McConville, et al. · Cancer Research
Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
2009 · Lillian L. Siu, Sebastien J. Hotte, et al. · Molecular Cancer Therapeutics
Works count: 21
Citation count: 477
H-index: 9
I10-index: 8
Year
Topic
Type